Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
Titel:
Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial
Auteur:
Aboud, Michael Kaplan, Richard Lombaard, Johannes Zhang, Fujie Hidalgo, José A Mamedova, Elmira Losso, Marcelo H Chetchotisakd, Ploenchan Brites, Carlos Sievers, Jörg Brown, Dannae Hopking, Judy Underwood, Mark Nascimento, Maria Claudia Punekar, Yogesh Gartland, Martin Smith, Kimberly